Discover the Intricacies of Complement Pathways to Accelerate Clinical Validation & Maximize Complement-Targeting in the Pan-Disease Setting

Built with Alexion, Apellis and Annexon, the 5th Complement-based Drug Development Summit returns for its fifth year as the definitive industry dedicated forum to maximize complement-targeting in the pan-disease setting.

With pivotal clinical readouts poised to be released in 2021, this year’s summit will once again unite thought leaders in complement-based drug development.

Expect to be involved in interactive discussions on:

• How dysregulated complement signaling contributes to disease and how to identify novel drug targets up and downstream of C3 and C5
• Preclinical and clinical pipeline progress of diverse drug modalities, including gene therapy approaches, small molecule inhibitors, antibodies, protease inhibitors, nucleic acids & more!
• Leveraging complement proteins in precision-based medicine as disease biomarkers and companion diagnostics
• Addressing clinical challenges of complement-targeted therapeutic sequencing, combinations and timing of administration
• Expanding the clinical utility of complement inhibitors across rare diseases, as well as autoimmune, ophthalmic, neurological and cancer settings

New for this year, you’ll have a two-tracked agenda with more speakers, more content and more networking opportunities than ever before! As the growth potential of novel complement-targeting therapeutics becomes apparent, join the conversation to realize the clinical and commercial potential of complement proteins as pan-disease targets!

To know more about 5th Complement-based Drug Development Summit please click here.